3 assets in Transitional Cell Carcinoma

Therapeutic assets addressing Transitional Cell Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Muamycin Transitional Cell Carcinoma	UroGen Pharma Ltd.	P3	B (63)
Ipilimumab Transitional Cell Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Nivolumab Transitional Cell Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)